12.01.2010
Clinical Cancer Research (2010) 16:5892-5899
Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin (NPI-2358) in Patients with Solid Tumors or Lymphomas
BREAKING NEWS
BeyondSpring announces submission of New Drug Application (NDA) to U.S. FDA and China NMPA for Plinabulin and G-CSF combination for the prevention of chemotherapy-induced neutropenia (CIN).
Read more